Evidence map›Paper›PMID 41583445›Full record

ReviewFrontiers in immunology2025

Covalent organic frameworks for cancer immunotherapy: mechanisms, applications, and prospects.

Yutao Zou, Min Chen, Jiayi Chen, Weiqi Wang, Xiaohua Zheng

Abstract readReview
In one paragraph

Review in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Yutao Zou *The People's Hospital of Danyang, Affiliated Danyang Hospital of Nantong University, Danyang, China.
Min Chen *School of Pharmacy, Nantong University, Nantong, Jiangsu, China.
Jiayi ChenSchool of Pharmacy, Nantong University, Nantong, Jiangsu, China.
Weiqi WangSchool of Pharmacy, Nantong University, Nantong, Jiangsu, China.
Xiaohua ZhengSchool of Pharmacy, Nantong University, Nantong, Jiangsu, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Covalent organic frameworks (COFs) have emerged as promising candidates in cancer immunotherapy, owing to their tunable pore structures, versatile functionality, and favorable biocompatibility. This review systematically highlights recent advances in COF-based materials that enhance immunotherapeutic efficacy through multiple strategies. Particular emphasis is placed on functionalized COFs for remodeling the immunosuppressive tumor microenvironment, by alleviating hypoxia and depleting glutathione, and their role as core sensitizers in various therapeutic modalities, including photodynamic, sonodynamic, radiotherapy, and chemodynamic therapy, to efficiently trigger immunogenic cell death (ICD). In addition, we comprehensively summarize how strategic structural engineering enhances phototherapeutic efficacy. This includes modulating the metal ions incorporated into the COF, controlling COF stacking modes, and adjusting the planarity or conformational twist of the building units to precisely tune bandgap energy and light absorption properties, thereby promoting stronger ICD induction. Furthermore, COFs serve as intelligent delivery platforms capable of controlled release of immune adjuvants and checkpoint inhibitors. The discussion also extends to cutting-edge applications, such as imaging-guided therapy, induction of tertiary lymphoid structure (TLS) formation, and activation of abscopal effects. These developments discussed in this review underscore the immense potential of COFs as multifunctional nanoplatforms in advancing effective and precise combination cancer immunotherapy. The insights provided in this review offer valuable reference for the biomedical applications of COFs, particularly in the integrated development of multimodal therapies and immunotherapy.

Indexed as

ImmunotherapyMetal-Organic FrameworksNeoplasmsAnimalsHumansImmunogenic Cell DeathPhotochemotherapyTumor MicroenvironmentMetal-Organic Frameworkscancer immunotherapycovalent organic frameworksimmunogenic cell deathimmunosuppressive tumor microenvironmentphotodynamic therapy

Identifiers

PMID41583445
PMCPMC12823972

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.